The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Aurora Kinase B Market Expected To Reach Based On Its 2026 Value?
The aurora kinase b market size has witnessed swift growth over recent years. It is projected to expand from $1.27 billion in 2025 to $1.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. This historical increase can be attributed to various factors such as advancements in molecular oncology research, the identification of aurora kinase b as a cancer target, the expansion of clinical trial infrastructure, escalating investment in targeted cancer therapies, and progress in kinase inhibitor development.
The aurora kinase b market size is projected for substantial expansion in the coming years. It is anticipated to reach $2.22 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This growth over the forecast period stems from escalating demand for precision cancer therapeutics, the broadening of personalized medicine approaches, increased activity in oncology clinical trials, rising investments in novel kinase inhibitors, and improved regulatory support for targeted oncology drugs. Significant trends during this period include the accelerated development of selective aurora kinase b inhibitors, a heightened emphasis on combination oncology therapies, the expansion of precision oncology drug pipelines, an increasing focus on mitotic targeted therapies, and enhanced biomarker-based patient stratification.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp
Which Key Factors Are Driving The Aurora Kinase B Market Growth?
The growing occurrence of cancer is predicted to propel the expansion of the aurora kinase B market in the future. Cancer is defined as a range of diseases marked by the uncontrolled proliferation and dissemination of abnormal cells, capable of invading nearby tissues and spreading to other body parts. The increase in cancer cases is attributed to factors like an aging populace, evolving lifestyles, environmental exposures, and enhanced detection and diagnosis. Aurora kinase B is crucial in mitosis, and its overexpression is connected to chromosomal instability and cancer advancement. It is frequently targeted in cancer therapies because of its involvement in tumor cell division. For example, the World Health Organization reported that an estimated 20 million new cancer cases were recorded in 2022, alongside 9.7 million deaths. By 2050, new cancer cases are anticipated to surpass 35 million, representing a 77% increase from 2022. Consequently, the rising incidence of cancer is driving the growth of the aurora kinase B market.
How Are Different Segments Classified In The Aurora Kinase B Market Segment Analysis?
The aurora kinase b market covered in this report is segmented –
1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types
2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications
3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811
2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies
3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib
4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies
5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials
6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology
Which Trends Are Influencing Demand In The Aurora Kinase B Market?
Major entities in the aurora kinase B market are developing novel products, such as aurora kinase inhibitors, designed to specifically disrupt crucial processes in cell division. These inhibitors are drugs engineered to block the activity of Aurora kinases, which are critical for cell division, thereby interrupting cancer cell proliferation and potentially reducing tumor growth. For instance, in June 2023, Ellipses Pharma, a UK-based biotechnology company, announced U.S. Food and Drug Administration (FDA) approval for its EP0042, a dual FLT-3 and Aurora kinase inhibitor. EP0042 is under development as a treatment for acute myeloid leukemia (AML) and functions as an inhibitor targeting both FLT3 and Aurora kinase. This strategy is specifically formulated for AML patients who have become resistant to FLT3 inhibitors. Research has demonstrated that dual inhibition of FLT3 and Aurora kinase can overcome acquired resistance to selective FLT3 inhibition both in vitro and in vivo.
Who Are The Companies Driving Activity In The Aurora Kinase B Market?
Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc
Get The Full Aurora Kinase B Market Report:
https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report
Which Region Is The Largest In The Aurora Kinase B Market?
North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Aurora Kinase B Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report
Browse Through More Reports Similar to the Global Aurora Kinase B Market 2026, By The Business Research Company
Cancer Biologics Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report
Skin Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report
Pancreatic Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model